Posted by Michael Wonder on 04 Dec 2020
enGene receives fast track designation for EG-70 for the treatment of non-muscle invasive bladder cancer
3 December 2020 - enGene announced today that the U.S. FDA has granted fast track designation to enGene for EG-70, the company's lead investigational non-viral gene therapy for the treatment of patients with Bacille Calmette-Guerin unresponsive non-muscle invasive bladder cancer.
In addition to developing EG-70 for BCG unresponsive non-muscle invasive bladder cancer, enGene is developing unique genetic medicines for respiratory indications and the company is evolving its technology to enable applications in multiple mucosal tissues with areas of high unmet medical need.
